RECQL4A Antibody

What are the optimal validation methods for RECQL4 antibodies?

When validating RECQL4 antibodies, researchers should employ multiple complementary approaches to ensure specificity. The gold standard involves comparing antibody reactivity in wild-type versus RECQL4 knockout or knockdown models. Western blotting should detect a primary band at approximately 73 kDa, matching RECQL4's calculated molecular weight . Additionally, validation should include:

• Peptide competition assays to confirm epitope specificity

• Cross-validation with multiple antibodies targeting different RECQL4 epitopes

• Verification of reactivity across species if conducting comparative studies (human, mouse, rat samples show confirmed reactivity with some commercial antibodies)

Tissue-specific expression patterns can provide further validation, as demonstrated by differential expression observed across mouse tissues including testis, skeletal muscle, and kidney .

What are the recommended conditions for Western blotting with RECQL4 antibodies?

For optimal Western blot results with RECQL4 antibodies, consider the following protocol parameters:

Sample preparation should include phosphatase inhibitors if analyzing RECQL4 phosphorylation status. For challenging samples, optimization may require sample-dependent titration to achieve optimal signal-to-noise ratio .

How should researchers interpret variations in RECQL4 band patterns across different cell lines?

Variations in RECQL4 band patterns across different cell lines require careful interpretation, considering multiple biological and technical factors:

Post-translational modifications significantly impact RECQL4 detection, with phosphorylation being particularly relevant given RECQL4's regulation by DNA damage response kinases like ATM and ATR . Higher molecular weight bands may represent modified forms of RECQL4, while multiple bands near the expected size could indicate alternative splicing or partial proteolytic degradation.

For accurate interpretation:

• Always include positive and negative controls specific to your experimental system

• Document cell line-specific RECQL4 expression profiles as baseline references

• Consider analyzing nuclear and cytoplasmic fractions separately, as RECQL4 shuttles between compartments depending on cellular state

• When comparing cancer versus normal tissue samples, account for the significantly elevated RECQL4 expression observed in many malignancies, including ESCC

If discrepancies persist, verify antibody specificity using siRNA-mediated knockdown in the specific cell lines being studied.

How can researchers effectively use RECQL4 antibodies to study its interaction with PARP1 in DNA damage response?

Investigating the functional interaction between RECQL4 and PARP1 requires sophisticated methodological approaches beyond standard immunoblotting:

Co-immunoprecipitation (Co-IP) experiments should be optimized with low-stringency buffers to preserve protein-protein interactions. When using RECQL4 antibodies for pull-down, researchers should:

• Include both PARP inhibitors and PARP1 antibodies as experimental controls

• Perform reciprocal Co-IPs (PARP1 pull-down followed by RECQL4 detection) to confirm interactions

• Consider proximity ligation assays (PLA) to visualize endogenous RECQL4-PARP1 interactions in situ

Recent research demonstrates that PARP1 facilitates RECQL4 recruitment to DNA damage sites and enhances its strand annealing activity during repair processes . To study this:

• Design experiments comparing wild-type and K508A helicase-inactive RECQL4 variants

• Implement laser microirradiation combined with live-cell imaging to track RECQL4 recruitment kinetics

• Analyze the impact of PARP inhibitors on RECQL4 localization and function

The helicase-inactive RECQL4 K508A variant retains DNA binding and strand annealing activity but lacks helicase and ATPase functions . This variant serves as an excellent tool for dissecting the specific contributions of RECQL4's distinct domains to PARP1-mediated recruitment and repair functions.

What methodological approaches help resolve contradictory data regarding RECQL4's role in alternative non-homologous end joining (alt-NHEJ)?

Researchers encountering contradictory results regarding RECQL4's function in alt-NHEJ should implement systematic troubleshooting strategies:

• Differentiate between RECQL4's roles in classical-NHEJ versus alt-NHEJ pathways:

  • Employ pathway-specific reporter assays that distinguish between repair mechanisms

  • Analyze repair outcomes at sequence resolution to identify microhomology usage characteristic of alt-NHEJ

• Address potential context-dependent functions:

  • Compare RECQL4's activity across different cell types with varying DNA repair pathway dependencies

  • Examine how cell cycle stage affects RECQL4's contribution to repair pathway choice

• Resolve protein functional domain contributions:

  • Utilize structure-function analysis with domain-specific mutations

  • The K508A helicase-inactive variant demonstrates that RECQL4's annealing capacity functions independently of its helicase activity

For biochemical confirmation, in vitro assays should test RECQL4's ability to displace RPA from ssDNA to facilitate microhomology annealing. Research shows that RECQL4 exhibits modest ssDNA annealing in the presence of RPA, whereas other RecQ helicases like BLM do not demonstrate this activity under similar conditions .

How should researchers design experiments to investigate RECQL4's role in MHC class II-mediated immune signaling?

Investigating RECQL4's regulation of MHC class II expression requires multifaceted experimental designs spanning genomic, proteomic, and functional immunology approaches:

Proteomics analysis reveals that RECQL4 overexpression downregulates multiple MHC-II molecules, including HLA-DMA, HLA-DMB, HLA-DPB1, HLA-DQA1, HLA-DQB1, and HLA-DRB1 . To further characterize this regulatory mechanism:

• Transcriptional regulation analysis:

  • Perform ChIP-seq to determine if RECQL4 directly associates with MHC-II gene promoters

  • Analyze the class II major histocompatibility complex transactivator (CIITA) expression and activity, which has been identified as a mediator bridging RECQL4's regulation of MHC-II

• Flow cytometry-based approaches:

  • Quantify surface MHC-II expression following RECQL4 modulation

  • Assess the functional impact on antigen presentation to CD4+ T cells

• In vivo validation:

  • Implement murine models with conditional RECQL4 expression in tumor cells

  • Analyze tumors for immune infiltration patterns, particularly focusing on CD4+ T cells, CD8+ T cells, and dendritic cells, which show negative correlation with RECQL4 expression

• Clinical correlation studies:

  • Stratify patient samples by RECQL4 expression levels

  • Compare immune scores, tumor purity, and TIARA-PD-1 scores between RECQL4-high and RECQL4-low groups

The significant correlation between high RECQL4 expression and lower immune scores (p=6.6e-08) and higher tumor purity (p=2.34e-05) provides robust starting points for hypothesis testing .

How can RECQL4 antibodies be utilized to evaluate potential biomarker applications in cancer immunotherapy?

RECQL4 shows significant promise as a predictive biomarker for immunotherapy response, particularly for immune checkpoint inhibitors (ICIs). Researchers should implement these methodological approaches for biomarker development:

• Retrospective analysis of patient cohorts:

  • Standardize RECQL4 immunohistochemistry protocols with validated antibodies

  • Establish scoring criteria for high versus low RECQL4 expression

  • Correlate expression with clinical outcomes in ICI-treated patients

• Multi-parameter biomarker panels:

  • Combine RECQL4 detection with established biomarkers like PD-L1, tumor mutational burden, and immune infiltration metrics

  • Develop integrated prediction models incorporating RECQL4 status

• Longitudinal assessment:

  • Monitor RECQL4 expression before, during, and after immunotherapy

  • Evaluate its potential as a dynamic biomarker of acquired resistance

Research has established that high RECQL4 expression correlates with significantly reduced response to anti-PD-1 therapy, as evidenced by lower TIARA-PD-1 scores in RECQL4-high samples (p=0.028) . Additionally, high RECQL4 expression limits survival and functions as an independent prognostic factor in melanoma patients .

The mechanism appears linked to RECQL4's promotion of an immune-evasive phenotype through downregulation of MHC-II molecules, which impacts T-cell-mediated tumor recognition and plays a critical role in ICI response .

What controls and normalization methods are essential when analyzing RECQL4 expression across diverse cancer types?

When analyzing RECQL4 expression across diverse cancer types, researchers must implement rigorous controls and normalization strategies:

• Technical normalization approaches:

  • Employ multiple reference genes for qRT-PCR studies, selecting those with stable expression across tissue types

  • For Western blotting, use total protein normalization methods (e.g., stain-free technology) in addition to housekeeping controls

  • Include recombinant RECQL4 protein standards for absolute quantification

• Biological reference samples:

  • Include matched normal tissue controls whenever possible

  • Establish tissue-specific RECQL4 expression baselines

  • Consider cell-type heterogeneity when analyzing whole-tissue samples

• Computational adjustments for complex datasets:

  • Apply tumor purity adjustments when analyzing genomic or transcriptomic data

  • Use partial Spearman's correlation adjusted by tumor purity when correlating RECQL4 with immune cell infiltration

In pan-cancer analyses encompassing 25,775 patients, controlling for cancer-type specific effects is essential . For melanoma-specific studies, researchers should stratify by genomic subtypes (e.g., BRAF-mutant, NRAS-mutant, NF1-mutant, or triple wild-type) to account for potential subtype-specific RECQL4 functions.

How should researchers design experiments to validate the causal relationship between RECQL4 activity and immunotherapy resistance?

Establishing causality between RECQL4 activity and immunotherapy resistance requires sophisticated experimental designs spanning in vitro, in vivo, and ex vivo approaches:

• Genetic modulation studies:

  • Generate stable RECQL4 knockout, knockdown, and overexpression models in relevant cancer cell lines

  • Engineer domain-specific RECQL4 mutants (e.g., K508A helicase-inactive variant) to dissect mechanistic contributions

  • Implement inducible systems to model temporal aspects of RECQL4-mediated resistance

• Functional immunology assays:

  • Conduct co-culture experiments with T cells and RECQL4-modulated cancer cells

  • Measure cytotoxicity, T cell activation, and cytokine production endpoints

  • Develop 3D co-culture systems incorporating additional immune cell types

• In vivo validation models:

  • Establish syngeneic mouse models with RECQL4-modulated tumors

  • Administer immune checkpoint inhibitors and monitor therapeutic response

  • Analyze tumor-infiltrating lymphocytes and their functional status

• Therapeutic intervention strategies:

  • Test whether pharmacological inhibition of RECQL4 can restore sensitivity to immunotherapy

  • Investigate combination approaches targeting both RECQL4 and immune checkpoints

Research has demonstrated that high RECQL4 expression correlates with immune-evasive phenotypes characterized by lower immune infiltration, particularly of CD4+ and CD8+ T cells (p=3.69e-02 and 2.70e-04, respectively) . Mechanistically, this appears mediated through RECQL4's downregulation of MHC-II molecules, as validated through proteomics analysis of cells overexpressing wild-type versus mutant RECQL4 .